PLUS1
19.74
-1.71 (-7.97%)
-1.71 (-7.97%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Mirum Pharmaceuticals Inc | MIRM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.71 | -7.97% | 19.74 | 17:37:40 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 19.74 | 19.67 | 21.965 | 21.56 | 21.45 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 19.74 | 25.35 | 5.61 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,295 | 208,513 | $ 20.69 | $ 4,314,460 | 82,191 | 6.5126 - 28.31 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:29:08 | 44 | $ 19.7417 | USD |
Mirum Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 501.38M | 25.40M | 11.86M | $ - | $ - | -2.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 0.10% |
Mirum Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/11/2020 | 16:30 | Business Wire | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq.. |
| 9/11/2020 | 07:00 | Business Wire | Mirum Pharmaceuticals to Present at Investor Conferences in.. |
| 9/01/2020 | 09:00 | Business Wire | Mirum Pharmaceuticals Initiates Rolling Submission of a New.. |
| 8/29/2020 | 08:45 | Business Wire | Mirum Pharmaceuticals Presents Maralixibat Five-Year.. |
| 8/13/2020 | 06:04 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 8/11/2020 | 17:30 | Business Wire | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq.. |
| 8/10/2020 | 16:14 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MIRM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.70 | 22.345 | 18.14 | 20.83 | 52,556 | 0.04 | 0.2% |
| 1 Month | 24.18 | 26.99 | 18.14 | 21.64 | 81,395 | -4.44 | -18.36% |
| 3 Months | 20.57 | 27.43 | 17.834 | 21.89 | 71,481 | -0.83 | -4.04% |
| 6 Months | 10.32 | 27.43 | 9.14 | 18.64 | 76,654 | 9.42 | 91.28% |
| 1 Year | 9.43 | 28.31 | 6.5126 | 18.48 | 139,698 | 10.31 | 109.33% |
| 3 Years | 13.00 | 28.31 | 6.5126 | 18.03 | 130,778 | 6.74 | 51.85% |
| 5 Years | 13.00 | 28.31 | 6.5126 | 18.03 | 130,778 | 6.74 | 51.85% |
Mirum Pharmaceuticals Description
| Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
